Drug Resistance and Cardiovascular Safety of Second-Generation Anti-Androgens in Patients with Advanced Prostate Cancer
DOI:
https://doi.org/10.31661/gmj.v11i.2727Keywords:
Second-Generation Antiandrogens, Efficacy, Receptors, Androgen, Cardiosafety, CardiotoxicityAbstract
Prostate cancer is recognized as one of the most common cancers affecting the male population. The prostate is revealed to be a hormone-dependent tissue as testosterone and dihydrotestosterone could bind to the androgen receptor, activate it, and initiate the nuclear translocation of this receptor which is followed by subsequent signaling cascades. Regarding this androgen dependency of the prostate, it is believed that androgen deprivation therapies are able to confront aggressive prostate cancer as first-line treatment. However, prostate cancer could overcome hormone deprivation strategies through a number of cellular mechanisms, such as intratumoral androgen production and the production of ligand-independent androgen receptor splice variants, which are known clinically as castration-resistant prostate cancer. Due to the limited efficacy of first-generation antiandrogens in complete blockage of androgen receptor activity, recently, four second-generation anti-androgens, including abiraterone acetate, enzalutamide, apalutamide, and darolutamide approved by the Food and Drug Administration, and considered standard of care for patients with advanced prostate cancer. Nevertheless, prostate cancer cells may acquire drug-resistance mechanisms to overcome these novel chemotherapeutics. Furthermore, potential adverse effects on nontargeted organs such as the cardiovascular system, are possible. Hence, the current study aimed to review the efficacy and cardio-safety of these novel therapeutical strategies.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
https://doi.org/10.3322/caac.21551
PMid:30620402
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
https://doi.org/10.3322/caac.21492
PMid:30207593
Goodarzi E, Beiranvand R, Mosavi-Jarrahi A, Naemi H, Khazaei Z. Epidemiology incidence and mortality worldwide common cancers in males and their relationship with the human development index (HDI): an ecological study updated in the world. J Contemp Med Sci. 2019;5(6):281-303.
https://doi.org/10.22317/jcms.v5i6.664
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18(5):282-301.
https://doi.org/10.1038/s41585-021-00442-8
PMid:33692499
Bashir MN. Epidemiology of prostate cancer. Asian Pac J Cancer Prev. 2015;16(13):5137-41.
https://doi.org/10.7314/APJCP.2015.16.13.5137
PMid:26225642
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, et al. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022;257(3):274-84.
https://doi.org/10.1002/path.5887
PMid:35220606 PMCid:PMC9311708
Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, et al. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res. 2022;41(1):214.
https://doi.org/10.1186/s13046-022-02406-1
PMid:35773731 PMCid:PMC9248128
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.
https://doi.org/10.1038/s41572-020-00243-0
PMid:33542230
Okpua NC, Okekpa SI, Njaka S, Emeh AN. Clinical diagnosis of prostate cancer using digital rectal examination and prostate-specific antigen tests: a systematic review and meta-analysis of sensitivity and specificity. AFJU. 2021;27(1):1-9.
https://doi.org/10.1186/s12301-021-00129-x
Koo KM, Mainwaring PN, Tomlins SA, Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol. 2019;16(5):302-17.
https://doi.org/10.1038/s41585-019-0178-2
PMid:30962568
D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M-H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21(11):2163-72.
https://doi.org/10.1200/JCO.2003.01.075
PMid:12775742
Wallis CJ, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(1):21-30.
https://doi.org/10.1016/j.eururo.2015.11.010
PMid:26700655
Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, et al. The influence of BRCA2 mutation on localized prostate cancer. Nat Rev Urol. 2019;16(5):281-90.
https://doi.org/10.1038/s41585-019-0164-8
PMid:30808988
Chen J, Oromendia C, Halpern JA, Ballman KV. National trends in management of localized prostate cancer: A population based analysis 2004â€2013. The Prostate. 2018;78(7):512-20.
https://doi.org/10.1002/pros.23496
PMid:29542178
Bratt O, Carlsson S, Fransson P, Thellenberg Karlsson C, Stranne J, Kindblom J, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265-73.
https://doi.org/10.1080/21681805.2022.2094462
PMid:35811480
Health Commission of The People's Republic of China N. National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):270-88.
https://doi.org/10.21147/j.issn.1000-9604.2022.03.07
PMid:35873888 PMCid:PMC9273581
Schover LR, Van Der Kaaij M, Van Dorst E, Creutzberg C, Huyghe E, Kiserud CE. Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl. 2014;12(1):41-53.
https://doi.org/10.1016/j.ejcsup.2014.03.004
PMid:26217165 PMCid:PMC4250536
Trump D, Lau YK. Chemotherapy of prostate cancer: present and future. Curr Urol Rep. 2003;4(3):229-32. https://doi.org/10.1007/s11934-003-0074-3
PMid:12756087
Von Hoff DD, Rozencweig M, Slavik M, Muggia FM. Estramustine phosphate: A specific chemotherapeutic agent? J Urol. 1977;117(4):464-6.
https://doi.org/10.1016/S0022-5347(17)58499-2
PMid:850319
Dahllöf B, Billström A, Cabral F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 1993;53(19):4573-81.
Ghalie R, Edan G, Laurent M, Mauch E, Eisenman S, Hartung H, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology. 2002;59(6):909-13.
https://doi.org/10.1212/WNL.59.6.909
PMid:12297576
Rossato LG, Costa VM, Dallegrave E, Arbo M, Dinisâ€Oliveira RJ, Santosâ€Silva A, et al. Cumulative mitoxantroneâ€induced haematological and hepatic adverse effects in a subchronic in vivo study. Basic Clin Pharmacol Toxicol. 2014;114(3):254-62.
https://doi.org/10.1111/bcpt.12143
PMid:24119282
Hurwitz M. Chemotherapy in Prostate Cancer. Curr Oncol Rep. 2015;17(10):44.
https://doi.org/10.1007/s11912-015-0468-7
PMid:26216506
Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, et al. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. J Clin Invest. 2020;130(6):3287-98.
https://doi.org/10.1172/JCI132184
PMid:32478682 PMCid:PMC7259995
Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177(6): 2136-40.
https://doi.org/10.1016/j.juro.2007.01.143
PMid:17509300
Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer. 2017;24(12):T297-310.
https://doi.org/10.1530/ERC-17-0145
PMid:28814451 PMCid:PMC5669826
Hunter J. The Works of John Hunter, FRS. Cambridge University Press; 2015.
https://doi.org/10.1017/CBO9781316034804
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209-23.
https://doi.org/10.1001/archsurg.1941.01210140043004
James ND, De Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338-51.
https://doi.org/10.1056/NEJMoa1702900
PMid:28578639 PMCid:PMC5533216
Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020;78(2): 184-92.
https://doi.org/10.1016/j.eururo.2020.03.001
PMid:32273183
Sarkar A, Siddiqui MR, Fantus RJ, Hussain M, Halpern JA, Ross AE. Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy. Urol Case Rep. 2021;38:101657.
https://doi.org/10.1016/j.eucr.2021.101657
PMid:33868943 PMCid:PMC8040255
Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, et al. Does exist a differential impact of degarelix versus LHRH agonists on cardiovascular safety? Evidences from randomized and real-world studies. Front Endocrinol (Lausanne). 2021;12:687.
https://doi.org/10.3389/fendo.2021.695170
PMid:34194398 PMCid:PMC8237856
Bahl A, Rajappa S, Rawal S, Bakshi G, Murthy V, Patil K. A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix). Indian J Cancer. 2022;59(5):160.
Tan M, Li J, Xu HE, Melcher K, Yong E-l. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36(1):3-23.
https://doi.org/10.1038/aps.2014.18
PMid:24909511 PMCid:PMC4571323
Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, et al. Androgen receptor signaling pathway in prostate cancer: From genetics to clinical applications. Cells. 2020;9(12):2653.
https://doi.org/10.3390/cells9122653
PMid:33321757 PMCid:PMC7763510
Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, et al. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2022;82(6):584-98.
https://doi.org/10.1016/j.eururo.2022.08.002
PMid:35995644
Johnson DB, Sonthalia S. Flutamide. In StatPearls [Internet]. StatPearls Publishing; 2021.
Health NIo. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532-42.
https://doi.org/10.1001/jama.2017.7248
PMid:28655021
Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256-62.
https://doi.org/10.1016/j.eururo.2015.11.005
PMid:26610858
Fang T, Xue Zs, Li Jx, Liu Jk, Wu D, Li Mq, et al. Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by reducing expression of androgen receptor and 5α-reductase in a rat model. J Integr Med. 2021;19(3):258-64.
https://doi.org/10.1016/j.joim.2020.12.002
PMid:33341427
Hong GL, Park SR, Jung DY, Karunasagara S, Lee KP, Koh EJ, et al. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2. J Ethnopharmacol. 2020;250:112446.
https://doi.org/10.1016/j.jep.2019.112446
PMid:31812646
Jonnalagadda B, Arockiasamy S, Krishnamoorthy S. Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC). Life Sci. 2020;259:118208.
https://doi.org/10.1016/j.lfs.2020.118208
PMid:32763294
Dahiya V, Bagchi G. Non-canonical androgen signaling pathways and implications in prostate cancer. Biochim Biophys. 2022:119357.
https://doi.org/10.1016/j.bbamcr.2022.119357
PMid:36100060
Wilk M, Waśko-Grabowska A, Szmit S. Cardiovascular complications of prostate cancer treatment. Front Pharmacol. 2020;11:555475.
https://doi.org/10.3389/fphar.2020.555475
PMid:33414715 PMCid:PMC7783464
Fourcade RO, McLeod D. Tolerability of anti-androgens in the treatment of prostate cancer. UroOncology. 2004;4(1):5-13.
https://doi.org/10.1080/1561095042000191655
Guirguis K. Bicalutamide causes heart failure in an elderly patient with prostate cancer. Expert Opin Drug Saf. 2016;15(3):297-302.
https://doi.org/10.1517/14740338.2015.1131819
PMid:26745594
Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14(3):e000082.
https://doi.org/10.1161/HCG.0000000000000082
PMid:33896190
Muniyan S, Xi L, Datta K, Das A, Teply BA, Batra SK, et al. Cardiovascular risks and toxicity-The Achilles heel of androgen deprivation therapy in prostate cancer patients. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188383.
https://doi.org/10.1016/j.bbcan.2020.188383
PMid:32535158 PMCid:PMC7473503
Cruz-Topete D, Dominic P, Stokes KY. Uncovering sex-specific mechanisms of action of testosterone and redox balance. Redox Biol. 2020;31:101490.
https://doi.org/10.1016/j.redox.2020.101490
PMid:32169396 PMCid:PMC7212492
Samare-Najaf M, Samareh A, Jamali N, Abbasi A, Clark CC, Khorchani MJ, et al. Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review. Curr Cancer Ther Rev. 2021;17(3):234-43.
https://doi.org/10.2174/1573394717666210202103502
Park SJ, Yoder B, Li T. Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer. J Hematol Oncol Pharm. 2022;12(2):92-8.
Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002;168(2): 542-5.
https://doi.org/10.1016/S0022-5347(05)64675-7
PMid:12131305
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-60.
https://doi.org/10.1016/S1470-2045(14)71205-7
PMid:25601341
Rice MA, Malhotra SV, Stoyanova T. Second-generation anti-androgens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801.
https://doi.org/10.3389/fonc.2019.00801
PMid:31555580 PMCid:PMC6723105
Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, et al. Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsProstate Cancer Resistance to CYP17A1 Inhibitors. Cancer Res. 2011;71(20):6503-13.
https://doi.org/10.1158/0008-5472.CAN-11-0532
PMid:21868758 PMCid:PMC3209585
Chang K-H, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013;154(5):1074-84.
https://doi.org/10.1016/j.cell.2013.07.029
PMid:23993097 PMCid:PMC3931012
Crona DJ, Whang YE. Androgen receptor-dependent and-independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 2017;9(6):67.
https://doi.org/10.3390/cancers9060067
PMid:28604629 PMCid:PMC5483886
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation anti-androgen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-90. https://doi.org/10.1126/science.1168175
PMid:19359544 PMCid:PMC2981508
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-38.
https://doi.org/10.1056/NEJMoa1315815
PMid:25184630 PMCid:PMC4201502
Tucci M, Zichi C, Buttigliero C, Vignani F, Scagliotti GV, Di Maio M. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther. 2018;11:7353. https://doi.org/10.2147/OTT.S153764
PMid:30425524 PMCid:PMC6204864
Golias C, Iliadis I, Peschos D, Charalabopoulos K. Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol. 2009;31(1):3-8.
Chen X, Liu J, Cheng L, Li C, Zhang Z, Bai Y, et al. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castrationâ€resistant prostate cancer. The Prostate. 2020;80(3):256-66.
https://doi.org/10.1002/pros.23939 PMid:31856338
Velho PI, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FA, et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2020;77(1): 14-21.
https://doi.org/10.1016/j.eururo.2019.05.032
PMid:31176623 PMCid:PMC6893106
Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res. 2017;23(14):3544-51.
https://doi.org/10.1158/1078-0432.CCR-16-2509
PMid:28213364 PMCid:PMC5543693
Smith MR, Yu M, Small EJ. Apalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378(26):2542.
https://doi.org/10.1056/NEJMoa1715546
Smith MR, Thomas S, Chowdhury S, Olmos D, Li J, Mainwaring PN, et al. Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study. Cancer Res. 2018;78(13_Supplement):2605.
https://doi.org/10.1158/1538-7445.AM2018-2605
Rathkopf DE, Smith M, Ryan C, Berry W, Shore N, Liu G, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017;28(9):2264-71.
https://doi.org/10.1093/annonc/mdx283
PMid:28633425 PMCid:PMC5834046
George DJ, Waldeck AR, Guo H, Upton AJ. Number needed to harm (NNH) in patients with non-metastatic, castration-resistant prostate cancer (nmCRPC): A final analysis from the darolutamide (D), enzalutamide (E), and apalutamide (A) clinical trials. Am J Clin Oncol. 2022;40:(28_suppl): 326.
https://doi.org/10.1200/JCO.2022.40.28_suppl.326
Moilanen A-M, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5(1): 1-11.
https://doi.org/10.1038/srep12007
PMid:26137992 PMCid:PMC4490394
Zurth C, Sandmann S, Trummel D, Seidel D, Gieschen H. Blood-brain barrier penetration of [14C] darolutamide compared with [14C] enzalutamide in rats using whole body autoradiography. Am J Clin Oncol. 2018;36(6_suppl):345.
https://doi.org/10.1200/JCO.2018.36.6_suppl.345
Obinata D, Lawrence MG, Takayama K, Choo N, Risbridger GP, Takahashi S, et al. Recent discoveries in the androgen receptor pathway in castration-resistant prostate cancer. Front Oncol. 2020;10:581515.
https://doi.org/10.3389/fonc.2020.581515
PMid:33134178 PMCid:PMC7578370
Tolcher A, Chi K, Shore N, Pili R, Molina A, Acharya M, et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70(2):305-13.
https://doi.org/10.1007/s00280-012-1916-9
PMid:22752297 PMCid:PMC3405235
Riad M, Allison JS, Nayyal S, Hritani A. Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report. Eur Heart J Case Rep. 2021;5(12):ytab462.
https://doi.org/10.1093/ehjcr/ytab462
PMid:35187388 PMCid:PMC8849113
Mak B, Lin H-M, Kwan EM, Fettke H, Tran B, Davis ID, et al. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Med. 2022;20(1):1-14.
https://doi.org/10.1186/s12916-022-02298-0
PMid:35331214 PMCid:PMC8953070
Seong J-M, Shin D, Sung JW, Cho S, Yang J, Kang S, et al. Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study. J Cancer. 2020;11(14):4015.
https://doi.org/10.7150/jca.38237
PMid:32368283 PMCid:PMC7196249
Morales X, Garnica D, Isaza D, Isaza N, Durán-Torres F. Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation. BMC Cardiovasc Disord. 2021;21(1):1-6.
https://doi.org/10.1186/s12872-021-01945-3
PMid:33711933 PMCid:PMC7953541
Tsao PA, Estes JP, Griggs JJ, Smith DC, Caram ME. Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: Post-marketing experience. Clin Genitourin Cancer. 2019;17(3):e592-601.
https://doi.org/10.1016/j.clgc.2019.03.001
PMid:31023520
Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113(1):9-21.
https://doi.org/10.1016/j.acvd.2019.09.006
PMid:31685432
Tsugu T, Nagatomo Y, Nakajima Y, Kageyama T, Akise Y, Endo J, et al. Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer. J Med Ultrasound. 2019;46(2):239-43.
https://doi.org/10.1007/s10396-018-0897-7
PMid:30151629
Kim T-H, Jeong J-W, Song J-H, Lee K-R, Ahn S, Ahn S-H, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015;38(11):2076-82.
https://doi.org/10.1007/s12272-015-0592-9
PMid:25956695
Serrano Domingo JJ, Alonso Gordoa T, Lorca Ãlvaro J, Molina-Cerrillo J, BarquÃn GarcÃa A, MartÃnez Sáez O, et al. The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Ther Adv Urol. 2021;13:17562872211043341.
https://doi.org/10.1177/17562872211043341
PMid:34552666 PMCid:PMC8451255
Liu JM, Lin CC, Chen MF, Liu KL, Lin CF, Chen TH, et al. Risk of major adverse cardiovascular events among secondâ€line hormonal therapy for metastatic castrationâ€resistant prostate cancer: A realâ€world evidence study. The Prostate. 2021;81(3):194-201.
https://doi.org/10.1002/pros.24096
PMid:33393676
Sternberg CN, Castellano D, De Bono J, Fizazi K, Tombal B, Wülfing C, et al. Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study. Eur Urol. 2021;80(4):497-506.
https://doi.org/10.1016/j.eururo.2021.06.021
PMid:34274136
Cone EB, Reese S, Marchese M, Nabi J, McKay RR, Kilbridge KL, et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. EClinicalMedicine. 2021;36:100887.
https://doi.org/10.1016/j.eclinm.2021.100887
PMid:34308305 PMCid:PMC8257986
Moyad MA, Scholz MC. Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. Res Rep Urol. 2014;6:71.
https://doi.org/10.2147/RRU.S63136
PMid:25157338 PMCid:PMC4106964
Gheorghe ACD, Ciobanu A, Hodorogea AS, Radavoi GD, Jinga V, Nanea IT, et al. Evolution of electrocardiographic repolarization parameters during anti-androgen therapy in patients with prostate cancer and hypogonadism. Cardiovasc Toxicol. 2020;20(4):390-400.
https://doi.org/10.1007/s12012-020-09566-6
PMid:32152959 PMCid:PMC7266846
Salem J-E, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation. 2019;140(13):1070-80.
https://doi.org/10.1161/CIRCULATIONAHA.119.040162
PMid:31378084 PMCid:PMC6756939
Morales M, MartÃn-Vasallo P, Ãvila J. Genetic Profiling of Glucocorticoid (NR3C1) and Mineralocorticoid (NR3C2) Receptor Polymorphisms before Starting Therapy with Androgen Receptor Inhibitors: A Study of a Patient Who Developed Toxic Myocarditis after Enzalutamide Treatment. Biomedicines. 2022;10(6):1271.
https://doi.org/10.3390/biomedicines10061271
PMid:35740293 PMCid:PMC9220762
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153-63.
https://doi.org/10.1016/S1470-2045(15)00518-5
PMid:26774508
Belderbos BP, De Wit R, Chien C, Mitselos A, Hellemans P, Jiao J, et al. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2018;82(3):457-68.
https://doi.org/10.1007/s00280-018-3632-6
PMid:29974203 PMCid:PMC6105166
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, de Santana Gomes AJP, Chung BH, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019;20(11): 1518-30.
https://doi.org/10.1016/S1470-2045(19)30620-5
PMid:31578173
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.
https://doi.org/10.1056/NEJMoa1903307
PMid:31150574
Uemura H, Arai G, Uemura H, Suzuki H, Aoyama J, Hatayama T, et al. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study. Int J Urol. 2022;29(6):533-40.
https://doi.org/10.1111/iju.14843
PMid:35293030 PMCid:PMC9310605
Burki T. Darolutamide for non-metastatic, castration-resistant prostate cancer. Lancet Oncol. 2019;20(3):e139.
https://doi.org/10.1016/S1470-2045(19)30102-0
PMid:30799257
Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, et al. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. Int J Clin Oncol. 2021;26(3):578-90.
https://doi.org/10.1007/s10147-020-01824-5
PMid:33226524 PMCid:PMC7895789
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040-9.
https://doi.org/10.1056/NEJMoa2001342
PMid:32905676
Published
Issue
Section
License
Copyright (c) 2022 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
